<DOC>
	<DOC>NCT02357901</DOC>
	<brief_summary>This is a randomized, double-blind, placebo controlled, multisite study in male and female participants who are seeking treatment for opioid use disorder.</brief_summary>
	<brief_title>Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine</brief_title>
	<detailed_description>Participants will be inducted with sublingual film strip. This is a 24-week non-residential study with participants being randomized after meeting criteria. On Day 1 and Day 29 (± 2 days) participants will receive subcutaneous injections of high dose or placebo. Thereafter, participants will receive 4 injections (once every 28 days ± 2 days) of high or low doses or placebo.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Currently meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM5) criteria for moderate or severe opioid use disorder By medical history has met DSM5 criteria for moderate or severe opioid use disorder for the 3 months immediately prior to signing the informed consent form Is seeking medicationassisted treatment for opioid use disorder Is an appropriate candidate for opioid partialagonist medicationassisted treatment in the opinion of the Investigator or medically responsible physician Body mass index (BMI) of ≥ 18.0 to ≤ 35.0 kg/m^2 Current diagnosis other than opioid use disorder requiring chronic opioid treatment Current substance use disorder as defined by DSM5 criteria with regard to any substances other than opioids, cocaine, cannabis, tobacco, or alcohol. Positive urine drug screen (UDS) result at screening for cocaine or cannabis AND meets DSM5 criteria for either moderate or severe cocaine or cannabis use disorder, respectively Meets DSM5 criteria for moderate or severe alcohol use disorder Received medicationassisted treatment for opioid use disorder (e.g., methadone, buprenorphine) in the 90 days prior to providing written informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>